US FDA grants OK to Novartis' Afinitor in rare kidney tumours
This article was originally published in Scrip
Executive Summary
Novartis racked up another win for its kinase inhibitor Afinitor (everolimus), gaining the US FDA's OK to market the drug as the first medication in the US to treat adults with renal angiomyolipomas associated with tuberous sclerosis complex (TSC), a rare genetic disease that causes the growth of various non-cancerous tumors in the brain, kidney and other vital organs.